Ultimovacs ASA (STU:7UM) Long-Term Debt : €0.00 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Ultimovacs ASA Long-Term Debt?

Ultimovacs ASA's Long-Term Debt for the quarter that ended in Mar. 2024 was €0.00 Mil.

Ultimovacs ASA Long-Term Debt Historical Data

The historical data trend for Ultimovacs ASA's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultimovacs ASA Long-Term Debt Chart

Ultimovacs ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

Ultimovacs ASA Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

Ultimovacs ASA (STU:7UM) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Ultimovacs ASA Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Ultimovacs ASA's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Ultimovacs ASA (STU:7UM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (STU:7UM) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

ULTIo:Sweden ULTI:Norway

Address

Ullernchausseen 64, Oslo, NOR, 0379

Website

https://www.ultimovacs.com

Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.

Ultimovacs ASA (STU:7UM) Headlines

No Headlines